Tvardi Therapeutics Inc. (TVRD)
NASDAQ: TVRD
· Real-Time Price · USD
23.00
1.98 (9.42%)
At close: Apr 29, 2025, 3:56 PM
21.60
-6.09%
Pre-market: Apr 30, 2025, 04:19 AM EDT
Company Description
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need.
Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
Tvardi Therapeutics Inc.
| Country | United States |
| IPO Date | Apr 16, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | Imran Alibhai, Ph.D. |
Contact Details
Address: 2450 Holcombe Blvd, Suite X Houston, Texas United States | |
| Website | https://tvarditherapeutics.com BioSpace +4 |
Stock Details
| Ticker Symbol | TVRD |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 140755307 |
| ISIN Number | US1407553072 |
| Employer ID | - |
| SIC Code | n/a |